Navigation Links
Dosing for RVX-208 Phase 1a Clinical Study Completed
Date:4/22/2008

Phase 1a study objectives were met

TSX Exchange Symbol: RVX

CALGARY, April 22 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has completed dosing of its Phase 1a safety, tolerability and pharmacokinetics study for its lead drug candidate, RVX-208, which addresses the dyslipidemia market. "Initial results from the emerging data are very good," declared Donald J. McCaffrey, President & CEO of Resverlogix. "As reported earlier this year the most remarkable results from this study continue to be the outstanding pharmacokinetics (drugability) of RVX-208. With these successful results in hand we are now planning for our Phase 1b/2a trial which, pending discussions and approval from the FDA, we expect to start later this year."

The primary objectives of the Phase 1a trial were to examine the safety, tolerability and pharmacokinetics of RVX-208. This study successfully met those objectives. In addition to the completed Phase 1a human clinical trial, RVX-208 has been the subject of 126 preclinical studies to date, comprising safety, toxicity, pharmacokinetics and pharmacology studies. The Company has selected the dosages to be used in the 28-day Phase 1b/2a study.

"We are very pleased with these promising results which indicate that RVX-208 is a safe and well tolerated drug," stated Dr. Jan Johansson, MD, PhD, Senior Vice President Medical Affairs of Resverlogix. "We are in the process of finalizing the tables, figures and legends for this past study." A review of the pharmacokinetic data was recently presented at the Arteriosclerosis, Thrombosis and Vascular Biology conference in Atlanta, GA.

About Cardiovascular Disease (CVD)

CVD can be generally defined as any abnormal condition characterized by dysfunction of the heart and blood vessels. CVD includes atherosclerosis (especially coronary heart disease which can lead to heart
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
2. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
6. Immucor CEOs Italian Trial Moves Toward Second Phase
7. Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
10. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
11. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 ... a global clinical research organization , ... a definitive agreement to acquire all of ... ("QSI"), a leading provider of specialized pharmacovigilance ... to the collection, detection, assessment, monitoring, and ...
(Date:3/26/2015)... the popular news television program that airs in numerous markets ... actor James Earl Jones, has announced that it will address ... Botany is commonly described as the scientific study of plants, ... complicated than that. Scientists and other professionals study a wide ... bacteria known to man to the largest trees that grow ...
(Date:3/26/2015)... WriteResult, a premier provider of ePRO ... University’s School of Public Health and New Haven Farms ... 4 month-long project. The goal of the study was ... with free access to fresh produce and nutrition education ... like high blood pressure, diabetes and weight gain. Patients ...
(Date:3/25/2015)... Agnition announced today that it will ... airing for the first time at 7:30 a.m. CST ... will explore the extremely important role soil microbes perform ... patented Microbial Catalyst™ technology that enhances soil and plant ... will air again on April 28. , A biochemist ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2
... Vicus Therapeutics, LLC, an,oncology-focused, clinical-stage, biopharmaceutical ... Clinical Research and Development, is,scheduled to present ... Tri-Conference on March 28st at 1:35 p.m. ... San Francisco. Dr. Rao will focus on,considerations ...
... to HistoRx AQUA(R) ... for tissue biomarker analysis-, NEW HAVEN, Conn., March ... a three-year agreement with Eli Lilly and Company,(NYSE: ... tissue biomarker,analysis widely available to Lilly researchers and clinicians ...
... company on track for Phase I/II trial ... ... Genetics Inc.,(TSX: SBS), a biotechnology company developing a portfolio of therapeutic,proteins ... toxicology study in animals to demonstrate the safety and,comparability of its ...
Cached Biology Technology:HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership 2HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership 3SemBioSys initiates toxicology study for safflower-produced insulin 2SemBioSys initiates toxicology study for safflower-produced insulin 3
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
(Date:3/20/2015)... OXFORD, Conn. , March 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... Wocket® smart wallet is one of the products featured ... today, March 20th at 11:00 PM EST on the ... travels to Las Vegas , site ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... at the Oregon National Primate Research Center at Oregon ... gene that appears to control how stem cells become ... implications for the study of Parkinson's disease, brain and ... might be combated by replacing lost or damaged brain ...
... that produce bird feathers have been visualized and analyzed for ... journey that may ultimately shed light on human organ regeneration. ... the journal Nature, was performed by a group of prominent ... University of Southern California. , "What we found is that ...
... team of scientists is proposing that endangered California condors raised ... so that the birds can once again feast on the ... , The researchers from Stanford University and four other institutions ... early condors and their potential prey. Writing in the Nov. ...
Cached Biology News:OHSU discovery sheds light into how stem cells become brain cells 2USC researchers track down the stem cells that create feathers 2USC researchers track down the stem cells that create feathers 3Seal rookeries could provide a reliable food source for endangered California condors, study finds 2Seal rookeries could provide a reliable food source for endangered California condors, study finds 3Seal rookeries could provide a reliable food source for endangered California condors, study finds 4Seal rookeries could provide a reliable food source for endangered California condors, study finds 5
...
... designed to allow neomycin/kanamycin selection in ... loxP-PGK-gb2-neo-loxP template encodes the neomycin/kanamycin resistance ... (gb2) for expression of kanamycin resistance ... (PGK) for expression of neomycin resistance ...
... inch long PYREX NMR tubes are made from ... valves, and vacuum racks. They are designed for ... 500MHz. They have an O.D. of 4.97 + ... These NMR tubes can be used with the ...
... TProfessional Thermocycler combines top performance with exquisite ... high speed and unparalleled temperature uniformity. The ... programming in a spreadsheet or alternatively in ... Lid opens on the push of a ...
Biology Products: